Massie B M
Am J Cardiol. 1985 Dec 6;56(16):97H-100H. doi: 10.1016/0002-9149(85)90552-1.
As a result of concern about the safety and long-term toxicity of diuretics, there is a growing trend toward the use of alternative agents as initial therapy in essential hypertension. Worldwide, beta blockers and vasodilators, especially the calcium-channel blockers, are the most commonly used alternative agents. Several studies comparing these 2 classes of medications are reviewed. These studies indicate that verapamil, nifedipine and diltiazem are all comparable in efficacy to beta blockers. When combined, calcium-channel blockers and beta blockers produce additive responses. These agents may differ in the relation between the magnitude of their antihypertensive effect and patients' pretreatment plasma renin activity and age. Younger persons and those with high plasma renin activity tend to respond better to beta blockers; older subjects and those with low plasma renin activity are more consistently responsive to calcium-channel blockers. The choice of agent should be individualized, based upon accompanying illnesses, adverse-effect profile and demographic factors.
由于对利尿剂的安全性和长期毒性的关注,在原发性高血压的初始治疗中使用替代药物的趋势日益增长。在全球范围内,β受体阻滞剂和血管扩张剂,尤其是钙通道阻滞剂,是最常用的替代药物。本文综述了几项比较这两类药物的研究。这些研究表明,维拉帕米、硝苯地平和地尔硫䓬在疗效上均与β受体阻滞剂相当。钙通道阻滞剂和β受体阻滞剂联合使用时会产生相加反应。这些药物在降压效果的幅度与患者治疗前血浆肾素活性和年龄之间的关系上可能有所不同。年轻人和血浆肾素活性高的人对β受体阻滞剂的反应往往更好;老年受试者和血浆肾素活性低的人对钙通道阻滞剂的反应更一致。应根据伴随疾病、不良反应情况和人口统计学因素进行个体化用药选择。